EGFR及VEGFR抑制剂联合调强放疗治疗局部晚期EGFR突变阳性非小细胞肺癌的临床研究分析  

Clinical study and analysis of EGFR and VEGFR inhibitor combined with intensity-modulated radiotherapy in the treatment of locally advanced EGFR mutation positive non-small cell lung cancer

作　　者：陈玉茹[1] 和劲光[1] 李花妮 陈子彤[1] CHEN Yu-ru;HE Jin-guang;LI Hua-ni(Heze Municipal Hospital,Heze 274000,China)

机构地区：[1]菏泽市立医院,274000

出　　处：《中国实用医药》2020年第4期11-14,共4页China Practical Medicine

基　　金：EGFR及VEGFR抑制剂联合调强放疗治疗晚期EGFR突变阳性非小细胞肺癌的临床研究。

摘　　要：目的观察表皮生长因子受体(EGFR)及血管内皮生长因子受体(VEGFR)抑制剂联合调强放疗治疗局部晚期EGFR突变阳性非小细胞肺癌(NSCLC)的临床价值。方法 60例局部晚期EGFR突变阳性NSCLC患者,采用随机数字表法分为A组、B组和C组,每组20例。A组患者给予单纯调强放疗, B组患者给予EGFR抑制剂联合调强放疗, C组患者给予EGFR抑制剂、VEGFR抑制剂联合调强放疗。对比三组患者治疗前后肿瘤体积、癌胚抗原(CEA)水平、卡氏功能状态(KPS)评分及临床疗效、毒副反应、消化道反应、放射性肺炎发生情况。结果治疗前,三组肿瘤体积、CEA水平对比差异无统计学意义(P>0.05);治疗后, C组患者肿瘤体积小于A组、B组, CEA水平低于A组、B组,差异有统计学意义(P<0.05)。C组治疗总有效率为85.0%,高于A组的45.0%、B组的55.0%,差异有统计学意义(P<0.05)。A组、B组、C组患者毒副反应发生率分别为20.0%、25.0%、20.0%,比较差异无统计学意义(P>0.05)。C组患者消化道反应发生率为10.0%,低于A组的25.0%、B组的25.0%,但差异无统计学意义(P>0.05)。治疗前,三组患者KPS评分比较差异无统计学意义(P>0.05);治疗后,三组患者KPS评分均高于本组治疗前,且C组高于A组、B组,差异具有统计学意义(P<0.05)。C组患者放射性肺炎发生率为20.0%,低于A组的30.0%、B组的40.0%,但差异无统计学意义(P>0.05)。结论针对局部晚期EGFR突变阳性NSCLC患者行EGFR、VEGFR抑制剂联合调强放疗治疗,对于促进病灶缓解、改善患者生活质量作用显著,且不增加不良反应,值得临床借鉴。Objective To observe the clinical value of epidermal growth factor receptor(EGFR) and vascular endothelial growth factor receptor inhibitors(VEGFR) inhibitor combined with intensity-modulated radiotherapy in the treatment of locally advanced EGFR mutation positive non-small cell lung cancer(NSCLC). Methods A total of 60 patients with locally advanced EGFR mutation positive NSCLC were divided into group A, group B and group C by random number table method, with 20 cases in each group. Group A received intensitymodulated radiotherapy, group B received EGFR inhibitor combined with intensity-modulated radiotherapy, and group C received EGFR and VEGFR inhibitor combined with intensity-modulated radiotherapy. The tumor volume, carcinoembryonic antigen(CEA) level and Karnofsky performance status(KPS) score before and after treatment, clinical efficacy, occurrence of toxic and side effects, gastrointestinal reactions and radiation pneumonia were compared among three groups. Results Before treatment, there was no statistically significant difference in tumor volume, CEA level among three groups(P>0.05). After treatment, the tumor volume of group C was smaller than that of group A and B, and the CEA level of group C was lower than that of group A and B. Their difference was statistically significant(P<0.05). The total effective rate of treatment in group C was higher than 45.0% in group A and 55.0% in group B, and their difference was statistically significant(P<0.05). The incidence of toxic and side effects were 20.0%, 25.0% and 20.0% respectively in group A, group B and group C, and the difference was not statistically significant(P>0.05). The incidence of gastrointestinal reactions was 10.0% in group C, which was lower than 25.0% in group A, and 25.0% in group B, but the difference was not statistically significant(P>0.05). Before treatment, there was no statistically significant difference in KPS score among the three groups(P>0.05). After treatment, the KPS score in the three groups was higher than those before treatm

关 键 词：表皮生长因子受体 血管内皮生长因子受体抑制剂 调强放疗 表皮生长因子受体突变阳性 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]